

Cipla announces further investment in GoApptiv; to hold 22.99% stake in the digital tech company

Strengthens investment in channels of the future to expand patient reach

Mumbai, India; 14th December, 2023: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has agreed to further invest INR 42 crore (approx.) in digital tech company GoApptiv Private Limited (hereafter referred to as "GoApptiv"). In line with Cipla's ambition to strengthen investments in channels of the future, this development will further expand Cipla's presence across the healthcare continuum, especially to the underserved population by enabling greater access to lifesaving treatments.

With the completion of this deal, Cipla's total stake in GoApptiv will increase to 22.99% on a fully diluted basis. This is Cipla's third investment in GoApptiv, which will be made in a combination of equity shares and compulsorily convertible preference shares. GoApptiv has experienced significant expansion in underpenetrated areas and product lines following prior investments by Cipla in 2022 and 2020.

Commenting on the development, **Umang Vohra, MD Global CEO, Cipla Limited**, said, "Our long-standing partnership with GoApptiv has helped us increase penetration in underserved rural areas of India and address critical healthcare gaps where pharmaceutical coverage is limited. As we advance in the era of technology-driven healthcare, this expanded investment will not only enhance our collective abilities to deliver patient-centric solutions, but also furthers our digitisation agenda to drive Cipla's next phase of growth."

GoApptiv's use of technology to provide quality and affordable healthcare aligns with Cipla's commitment to making a positive impact on communities through innovative solutions. Cipla plans to continue supporting GoApptiv through further investment rounds, solidifying their partnership in addressing healthcare disparities in underserved regions of India.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sep'23), 2nd largest in the pharma prescription market in South Africa (IQVIA MAT Aug'23), and 4th largest by prescription in the US Gx inhalation products (IQVIA MAT Aug'23). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar

Cipla Ltd.

Regd. Office -Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

P +91 22 24826000 **F** +91 22 24826120 **W** www.cipla.com **E-Mail** contactus@cipla.com **Corporate Identity Number** L24239MH1935PLC002380

a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#)

Media Contacts:

Corporate Communications

Heena Kanal

E-Mail: Heena.kanal@cipla.com

Investor Relations

Ajinkya Pandharkar

E-Mail: Investor.Relations@cipla.com

About GoApptiv:

GoApptiv incorporated under the provisions of Companies Act, 2013, is a digital tech-company engaged in the business of offering digital solutions to pharmaceutical companies for increasing patient reach. It offers end to end business solutions including distribution, digital solutions, integrated brand sales management, digital marketing, patient support and healthcare data analytics, channel engagement etc., for healthcare companies.